I believe the sell off due to 2 factors:
1. Market expections - an update on financial/ cash position post balance date was expected but none given,
2. The surprise allocation of nearly all revenue to China. The malaysian contract was supposed to earn AUD$60m-$80m p.a. What has happened to the Malaysian contract? Once again a complete lack of explanation from the company. This has created a lack of confidence & confusion amongst investors.
Other negative points in the report:
1. Amortisation charge of $3.8m was only for 3 months - this year it will be approx. $15m, so profit will be reduced $15m, albeit a non-cash expense.
2. Significant bonuses paid to the directors.
On the plus side:
1. the accounts have been audited without change / qualification.
2. Intangibles value has been independently tested.
3. Chinese govt. must be paying as the receivables balance is less than the revenue figure.
I continue to hold but we need '010 guidance, explanation of Malaysian position & also a new contract to instill confidence in the product & management (almost a year since last contract win).
- Forums
- ASX - By Stock
- NBS
- annual report
annual report, page-15
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NBS (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.9¢ |
Change
0.000(0.00%) |
Mkt cap ! n/a |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online